Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Bone Morphogenetic Protein 2 (BMP2) antibody
|Synonyms||BMP2A, Bmp2a, AI467020, BMP2, bmp2-b, BMP-2, bmp2a, xbmp2, xBMP-2, MGC114605, MGC159940|
Alternatives Western Blotting (WB), ELISA
|9 references available|
|Quantity||0.1 mg (0.5 mg/ml)|
|Price||Product not available in this region.|
|Alternative name||BMP2 / BMP2A|
|Immunogen||Recombinant full length protein expressed in E. coli (Human).|
|Description||Bone Morphogenic Proteins (BMP) are members of the TGF-beta superfamily that affect bone and cartilage formation (Hogan 1996, Reddi 1998 and Francis-West et al. 1999). Mature BMPs are 30-38 kDa proteins that assume a TGF-beta -like cysteine knot configuration. Lovostatin increases bone formation by turning on the bmp-2 gene (Mundy et al. 1999). BMPs stimulate the production of specific bone matrix proteins and alter stromal cell and osteoclast proliferation (Macias et al. 1999, Lecanda et al. 1997). BMPs may also be an important factor for development of the viscera, with roles in cell proliferation, apoptosis, differentiation, and morphogenesis (Hogan 1996, Dale and Wardle 1999). BMPs appear to be responsible for normal dorsal/ventral patterning. Like TGF-beta, BMPs bind to a type II receptor, which then recruits the transducing type I receptor unit, activating the Smad protein signaling pathway (Massague 1994, Derynck 1997, Attisano 1993).|
|Specificity||Monoclonal anti-BMP-2 recognizes recombinant human BMP-2 by ELISA and immunoblotting. The antibody shows approximately 25% cross-reactivity with recombinant human BMP-4.|
|Application Notes||I-ELISA: Use at a concentration of 0.5-1 ug/ml to detect a limit of ~3 ng/well recombinant human BMP-2. WB: Use at a concentration of 1-2 ug/ml for human BMP-2 at 50 and 100 ng/lane under non-reducing and reducing conditions, respectively. Not tested in other applications. Optimal dilutions/concentrations should be determined by the end user.|
|Purification||Protein G affinity purified|
|Buffer||Phosphate buffered saline|
|Storage||Store at 4 C. Aliquot and store at -20 C long-term. Avoid repeated freezing and thawing.|
|Restrictions||For Research Use only|
Attisano, Cárcamo, Ventura et al.: "Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors." in: Cell, Vol. 75, Issue 4, pp. 671-80, 1993 (PubMed).
Hogan: "Bone morphogenetic proteins: multifunctional regulators of vertebrate development." in: Genes & development, Vol. 10, Issue 13, pp. 1580-94, 1996 (PubMed).
Lecanda, Avioli, Cheng: "Regulation of bone matrix protein expression and induction of differentiation of human osteoblasts and human bone marrow stromal cells by bone morphogenetic protein-2." in: Journal of cellular biochemistry, Vol. 67, Issue 3, pp. 386-96, 1997 (PubMed).
Derynck, Feng: "TGF-beta receptor signaling." in: Biochimica et biophysica acta, Vol. 1333, Issue 2, pp. F105-50, 1997 (PubMed).
Reddi: "Role of morphogenetic proteins in skeletal tissue engineering and regeneration." in: Nature biotechnology, Vol. 16, Issue 3, pp. 247-52, 1998 (PubMed).
Macias, Ganan, Rodriguez-Leon et al.: "Regulation by members of the transforming growth factor beta superfamily of the digital and interdigital fates of the autopodial limb mesoderm." in: Cell and tissue research, Vol. 296, Issue 1, pp. 95-102, 1999 (PubMed).
Francis-West, Parish, Lee et al.: "BMP/GDF-signalling interactions during synovial joint development." in: Cell and tissue research, Vol. 296, Issue 1, pp. 111-9, 1999 (PubMed).
Dale, Wardle: "A gradient of BMP activity specifies dorsal-ventral fates in early Xenopus embryos." in: Seminars in cell & developmental biology, Vol. 10, Issue 3, pp. 319-26, 1999 (PubMed).
Mundy, Garrett, Harris et al.: "Stimulation of bone formation in vitro and in rodents by statins." in: Science (New York, N.Y.), Vol. 286, Issue 5446, pp. 1946-9, 1999 (PubMed).